title: [Comparative study between 0.025% ketotifen fumarate and 0.1% olopatadine hydrochloride in the treatment of vernal keratoconjunctivitis].
abstract: OBJECTIVE
  To compare the topical use of 0.025% ketotifen fumarate and 0.1% olopatadine hydrochloride in the treatment of patients with vernal keratoconjunctivitis.
  
  
  METHODS
  A study performed in one center, simple masked, parallel-group compared ketotifen and olopatadine. These patients were evaluated on four visits during the treatment (days 1, 7, 14 and 21), defined by ratings scores. Adverse events were the main variable of safety rating.
  
  
  RESULTS
  On evaluating ocular itching, burning, tearing, conjunctival hyperemia, mucous discharge and photophobia, the ketotifen group showed a significant improvement of total signs and symptoms (p<0.05). Between the baseline and the 2nd visit, treatment with olopatadine resulted in decreased burning, but after the 4th visit, ketotifen was slightly better. Sand sensation, papillae and Horner-Trantas dots were not significantly different in both groups.
  
  
  CONCLUSIONS
  Both drugs were efficient and safe relieving the main symptoms and signs of vernal keratoconjunctivitis. Between the same timepoints, there was a significant difference in favor of ketotifen-treated patients (p<0.05), showing improvement of itching, tearing, conjunctival hyperemia, mucous discharge and photophobia.
authors.affiliation: Departamento de Oftalmologia, Faculdade de Ciências Médicas, Santa Casa de Misericórdia de São Paulo, Rua Afonso de Freitas 488, São Paulo, SP, CEP 04006-052 Brazil. witaks@yahoo.com.br
authors.forename: Wilson Takashi
authors.initials: WT
authors.lastname: Hida
authors.forename: Daniel Cruz
authors.initials: DC
authors.lastname: Nogueira
authors.forename: Arthur
authors.initials: A
authors.lastname: Schaefer
authors.forename: Paulo Elias Correa
authors.initials: PE
authors.lastname: Dantas
authors.forename: Maria Cristina Nishiwaki
authors.initials: MC
authors.lastname: Dantas
mesh_terms: D000287:Administration, Topical; D018926:Anti-Allergic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016009:Chi-Square Distribution; D002648:Child; D002675:Child, Preschool; D003233:Conjunctivitis, Allergic / Q000188:drug therapy*; D003990:Dibenzoxepins / Q000009:adverse effects / Q000627:therapeutic use*; D005128:Eye Diseases / Q000209:etiology*; D005260:Female; D006801:Humans; D007665:Ketotifen / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D000069605:Olopatadine Hydrochloride; D009883:Ophthalmic Solutions / Q000009:adverse effects / Q000627:therapeutic use; D011537:Pruritus / Q000209:etiology; D012621:Seasons; D016037:Single-Blind Method; D018709:Statistics, Nonparametric; D013666:Tears / Q000187:drug effects; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D018926:Anti-Allergic Agents; D003990:Dibenzoxepins; D009883:Ophthalmic Solutions; D000069605:Olopatadine Hydrochloride; D007665:Ketotifen